Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion - BRAVO

Description:

The goal of the BRAVO trial was to evaluate the safety and efficacy of the oral glycoprotein (GP) IIb/IIIa antagonist lotrafiban in patients with coronary and cerebrovascular disease.